CLL14 trial analysis

CLL14 trial analysis

CLL14: feasibility of fixed-duration frontline therapy in CLLПодробнее

CLL14: feasibility of fixed-duration frontline therapy in CLL

Othman Al Sawaf, ASCO20: Results of the Phase III CLL14 Trial for Chronic Lymphocytic LeukaemiaПодробнее

Othman Al Sawaf, ASCO20: Results of the Phase III CLL14 Trial for Chronic Lymphocytic Leukaemia

CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucilПодробнее

CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil

Dr. Mato on the CLL14 Trial Results in CLLПодробнее

Dr. Mato on the CLL14 Trial Results in CLL

CLL14: Venetoclax plus obinutuzumab in untreated CLLПодробнее

CLL14: Venetoclax plus obinutuzumab in untreated CLL

Dr. Siddiqi on the CLL14 Trial Results in CLLПодробнее

Dr. Siddiqi on the CLL14 Trial Results in CLL

CLL14: Venetoclax plus obinutuzumab for CLLПодробнее

CLL14: Venetoclax plus obinutuzumab for CLL

Novel Insights from the Randomized, Phase 3 CLL14 TrialПодробнее

Novel Insights from the Randomized, Phase 3 CLL14 Trial

Kirsten Fischer, Treatment of CLL from 2019 Onwards: CLL14 TrialПодробнее

Kirsten Fischer, Treatment of CLL from 2019 Onwards: CLL14 Trial

Othman Al-Sawaf, EHA, 2019 – Analysis of the CLL14 trialПодробнее

Othman Al-Sawaf, EHA, 2019 – Analysis of the CLL14 trial

Venetoclax plus obinutuzumab in CKT CLL: analysis from the CLL14 trialПодробнее

Venetoclax plus obinutuzumab in CKT CLL: analysis from the CLL14 trial

Updates from the CLL14 and CLL2-GiVe trials on CLLПодробнее

Updates from the CLL14 and CLL2-GiVe trials on CLL

Obinutuzumab and venetoclax for high-risk CLL: upcoming CLL14 trialПодробнее

Obinutuzumab and venetoclax for high-risk CLL: upcoming CLL14 trial

Lori A. Leslie, MD, elaborates on recent outcomes from the CLL14 trialПодробнее

Lori A. Leslie, MD, elaborates on recent outcomes from the CLL14 trial

CLL14 trial thoughtsПодробнее

CLL14 trial thoughts

Dr. Shadman on the CLL14 Trial in CLLПодробнее

Dr. Shadman on the CLL14 Trial in CLL

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?Подробнее

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?